Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Eric Wenzler, Keith A Rodvold

Abstract

Telavancin (TD-6424) was discovered in 2000 and became the first marketed semisynthetic lipoglycopeptide in 2009. This parenteral antibacterial agent has a dual mechanism of action and potent in vitro activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and isolates with reduced vancomycin susceptibility. Pharmacokinetic and pharmacodynamic analyses support the concentration-dependent activity and once-daily dosing regimen of telavancin. A changing regulatory approval process, manufacturing obstacles, and the termination of a commercialization partnership have challenged the development and marketing of telavancin. The commercial operations for telavancin have been restored, a new manufacturer has been secured, and reliable product supplies are available for clinical use. In addition, telavancin continues to be supported by ongoing clinical research with the recent launch of the Telavancin Observational Use Registry (TOUR; NCT02288234) in the United States and an international phase 3, randomized trial comparing telavancin with standard therapy for the treatment of patients with complicated S. aureus bacteremia, including endocarditis (NCT02208063).

References

Jan 1, 1997·Medicinal Research Reviews·A MalabarbaR C Thompson
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·John L PaceKoné Kaniga
Nov 19, 2003·Bioorganic & Medicinal Chemistry Letters·J Kevin Judice, John L Pace
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Sharath S HegdeJ Kevin Judice
Aug 12, 2004·The Journal of Antibiotics·Michael R LeadbetterJ Kevin Judice
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·J P ShawS Barriere
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·Heather K SunDavid P Nicolau
Jun 1, 2006·The Journal of Antimicrobial Chemotherapy·Noe ReyesSharath S Hegde
Nov 13, 2007·The Journal of Antimicrobial Chemotherapy·Sharath S HegdeStacey Difuntorum
Jul 1, 2008·The Journal of Antimicrobial Chemotherapy·Shekman L WongMichael R Goldberg
Nov 28, 2009·The International Journal of Artificial Organs·Jignes H PatelBruce Mueller
Mar 10, 2010·Journal of Pharmaceutical Sciences·David R LukeHaran T Schlamm
Apr 9, 2010·The Journal of Antimicrobial Chemotherapy·Heather Nace, Bennett Lorber
Jun 3, 2010·Antimicrobial Agents and Chemotherapy·Jeng-Pyng ShawMichael M Kitt
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Katherine A Laessig
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·UNKNOWN Infectious Diseases Society of America (IDSA)George Talbot
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alfred SorbelloSumati Nambiar
Sep 30, 2010·Antimicrobial Agents and Chemotherapy·Luis A Marcos, Bernard C Camins
Nov 17, 2010·Antimicrobial Agents and Chemotherapy·Alasdair P MacGowanKaren E Bowker
Dec 15, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ethan RubinsteinUNKNOWN ATTAIN Study Group
Aug 13, 2011·The Journal of Antimicrobial Chemotherapy·Jennifer D TwillaJustin B Usery
Dec 17, 2011·The Journal of Antimicrobial Chemotherapy·Luis A MarcosDavid K Warren
Jan 19, 2012·Antimicrobial Agents and Chemotherapy·Emil SamaraPhilip Worboys
May 24, 2012·The Annals of Pharmacotherapy·Mary Beth BrinkmanLucinda J Van Anglen
Apr 3, 2013·Antimicrobial Agents and Chemotherapy·Steven N LeonardMeghna D Patel
Jul 31, 2013·International Journal of Antimicrobial Agents·Martin E StryjewskiG Ralph Corey
Aug 2, 2013·Transplant Infectious Disease : an Official Journal of the Transplantation Society·T H SwartzG Patel
Dec 18, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Keith A Rodvold, Kevin W McConeghy
Jan 15, 2014·Antimicrobial Agents and Chemotherapy·G Ralph CoreySteven L Barriere

❮ Previous
Next ❯

Citations

Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Keith A Rodvold
May 10, 2016·Expert Opinion on Drug Metabolism & Toxicology·Liapikou Adamantia, Torres Antoni
Mar 16, 2017·Expert Review of Clinical Pharmacology·Ronald G HallKenna D Payne
Jan 10, 2018·Antimicrobial Agents and Chemotherapy·Kristen L BunnellKeith A Rodvold
Jan 15, 2018·Clinical Pharmacokinetics·Valentin Al Jalali, Markus Zeitlinger
Dec 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Megan Brafford May, Ashley Glode
Sep 25, 2016·Cold Spring Harbor Perspectives in Medicine·Daina ZengJohn L Pace
Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christian E Sandrock, Andrew F Shorr
Feb 2, 2021·Clinical Pharmacology and Therapeutics·Manjunath P Pai
Dec 1, 2017·ACS Chemical Biology·Bernhard KepplingerNicholas Edward Ellis Allenby

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.